Front | Back |
WHAT IS THE PURPOSE OF INCLUDING AN Rh CONTROL WHEDN INTERPRETING GROUP AB, D POS RED CELLS AFTER TESTING WITH LOW PROTEIN ANTI-D REAGENT
|
TO CONFIRM D TYPING RESULTS
|
MONOSPECIFIC AHG REAGENT CANTAIN WHAT ANTIBODY SPECIFICITIES
|
ANTI-IgG AND C3d
|
YOU HAVE ADDED IgG-SESITIZED CELLS TO A NEGATIVE INDIRECT ANITGLOBULIN TEST YOU OBSERVE AGGLUTINATION IN THE TUBE WHAT SITUATION WAS NOT CONTROLLED FOR AIN TESTING BY ADDING THESE CONTROL CELLS
|
THE ADDITION OF PATIENT SERUM
|
PART OF THE DAILY QUALITY CONTROL IN THE BLOOD BANK LAB IS THE TESTING ON REAGENT ANTISERA WITH CORRESPONDING ANTIGEN POSITIVE AND ANTIGEN NEGATIVE RED CELLLS WHAT DOWS THIS PRODEDURE ENSURE
|
ANTIBODY SPECIFICITY
|
GROUP O RED CELLS ARE USED A S A SOURCE FOR COMMERCIAL SCREENING CELLS BECAUSE OF WHAT
|
ABO ANTIBODIES DO NOT REACT WITH GROUP O CELLS
|
INFORMATION REGARDING REAGENT LLIMITATIONS IS LOCATED IN THE
|
PRODUCT INSERTS
|
WHAT REGULATORY AGENCY PROVIDES LICENSURE FOR BLOOD BANKING REAGENST
|
FDA
|
WHAT ANTIBODIE ARE PRESENT IN POLYSPECIFIC AHG REAGEN
|
ANTI-IgG AND ANTI-C3d
|
IN WHICH SOURCE ARE THE REGULATIONS REGARDING THE MANUFACTURING OF BLOOD BANKING REAGENTS PUBLISHED
|
CODE OF FEDERAL REGULATIONS
|
AFTER THE ADDITION OF MONOCLONAL BASED ANTI-D TO A PATIENTS RED CELL SUSPENSION AGGLUTINATION WAS OBSERVED WHAT IS THE INTERPERTATION OF THIS RESULT
|
PATIENT IS D POSITIVE
|
WHAT REAGENT WOULD BE SELECTED TO DETECT THE PRESENCE OF UNEXPECTED RED CELL ANTIBODIES
|
SCREEENING CELLS
|
SELECT THE METHOD THAT USES THE PRINCIPLE OF SIEVING TO SEPARATE LARGER AGGLUTINATES FROM SMALLER AGGLUTINATES IN Ag-aB REACTIONS
|
GEL TECHNOLOGY
|
TO DETERMINE THE SPECIFICITY OF A RED CELL ANTIGEN IN A PATIENT SAMPLE WHAT SOURCE OF ANTIBODY IS SELECTED
|
COMMERCIAL ANTISERA
|
TO DETERMIN THE PRESENCE OF A RED CELL ANTIBODY IN A PATEINT SMPLE WHAT SOURCE OF ANTIGEN IS SELECTED
|
COMMERCIAL REAGENT RED CELLS
|
WHAT REAGENTS ARE DERIVED FROM PLANT EXTRACTS
|
LECTINS
|